BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Soft Tissue Sarcoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Soft Tissue Sarcoma\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05679921-1918@assetmemo.bio
DTSTAMP:20261121T004448Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Votrient (Pazopanib): Phase 2 readout est. (NCT05679921)
DESCRIPTION:Votrient (Pazopanib)\, phase 2\, Soft Tissue Sarcoma.\nStudy: P
 azopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pazopanib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05679921
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05879146-3189@assetmemo.bio
DTSTAMP:20261121T004448Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nirogacestat: Phase 2 readout est. (NCT05879146)
DESCRIPTION:Nirogacestat\, phase 2\, Desmoid Tumors.\nStudy: Evaluation of 
 the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical 
 Study\nEstimated primary completion: 31 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nirogacestat#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05879146
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180695-1918@assetmemo.bio
DTSTAMP:20261121T004448Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Votrient (Pazopanib): Phase 1/2 readout est. (NCT05180695)
DESCRIPTION:Votrient (Pazopanib)\, phase 1/2\, Soft Tissue Sarcoma.\nStudy:
  HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic S
 oft Tissue Sarcomas\nEstimated primary completion: February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pazopanib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05180695
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170644-3189@assetmemo.bio
DTSTAMP:20261121T004448Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Nirogacestat: Phase 2 readout est. (NCT07170644)
DESCRIPTION:Nirogacestat\, phase 2\, Desmoid Tumors.\nStudy: A Study of Nir
 ogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (
 DT/AF)\nEstimated primary completion: 28 May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nirogacestat#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07170644
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05949099-3189@assetmemo.bio
DTSTAMP:20261121T004448Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Nirogacestat: Phase 2 readout est. (NCT05949099)
DESCRIPTION:Nirogacestat\, phase 2\, Desmoid Tumors.\nStudy: Study of Cryoa
 blation and Nirogacestat for Desmoid Tumor\nEstimated primary completion: 
 1 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niro
 gacestat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05949099
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239272-1918@assetmemo.bio
DTSTAMP:20261121T004448Z
DTSTART;VALUE=DATE:20340630
DTEND;VALUE=DATE:20340701
SUMMARY:Votrient (Pazopanib): Phase 1/2 readout est. (NCT06239272)
DESCRIPTION:Votrient (Pazopanib)\, phase 1/2\, Soft Tissue Sarcoma.\nStudy:
  NRSTS2021\, A Risk Adapted Study Evaluating Maintenance Pazopanib\, Limit
 ed Margin\, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomy
 osarcoma Soft Tissue Sarcoma (NRSTS)\nEstimated primary completion: June 2
 034. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pazopanib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06239272
URL:https://assetmemo.bio/drug/pazopanib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
